Skip to content

NeoGenomics NEO Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$146.14M-57.8%$159.62M-56.5%$164.12M-54.7%$154.72M-56.4%$346.19M+4.3%
$167.42M+10.7%$159.24M+5.8%$155.3M+2.6%$153.13M+4.5%$151.21M+7.8%
$29.84M+0.2%$28.57M+6.8%$28.46M+16.4%$34.17M+47.2%$29.77M+46.5%
$175K-20.1%$138K-99.3%$179K-99.0%$199K-98.9%$219K-98.9%
$373.68M-34.9%$376.29M-36.9%$382.47M-35.2%$392.55M-32.8%$573.93M0.0%
$83.66M-6.6%$84.83M-9.8%$85.47M-8.1%$85.46M-7.3%$89.6M+2.0%
$215.97M$209.06M$208.98M
$76.7M-1.4%$78.44M-1.4%$80.15M-1.6%$82.87M-1.0%$77.8M-10.1%
$524M+0.2%$524.34M+0.3%$524.34M+0.3%$524.14M+0.3%$522.77M0.0%
$265.45M-16.5%$286.53M-15.6%$280.72M-19.3%$288.35M-19.1%$317.87M-12.9%
$17.45M-16.8%$18.22M-15.3%$20.85M-8.5%$19.98M-13.2%$20.97M-10.7%
$157K+554%$36K-99.4%$63K-98.9%$43K-98.9%$24K-99.5%
$972.85M-5.3%$983.54M-5.6%$992.32M-5.6%$1B-5.4%$1.03B-3.7%
$1.35B-15.9%$1.36B-17.0%$1.37B-16.2%$1.39B-15.2%$1.6B-2.4%
$25.9M+59.8%$23.09M+6.9%$22.61M+36.9%$27.49M+60.0%$16.21M-11.6%
$40.58M+2.8%$47.58M-23.8%$51.3M-1.7%$48.56M-4.6%$39.49M+14.1%
$561K-51.8%$851K+108%$1.58M+168%$1.08M+11.5%$1.16M+1.7%
$4.83M+57.0%$4.78M+41.3%$4.51M+21.3%$4.05M+13.4%$3.08M-31.5%
$338K$386K$507K
$400K$500K$500K
$84.59M-69.8%$88.3M-70.7%$97.87M-67.0%$100.12M-65.5%$279.7M+265%
$61.46M+2.7%$62.82M+3.3%$64.33M+3.5%$66.62M+5.2%$59.86M-7.6%
$12.03M+0.9%$12.07M+2.5%$11.98M+3.3%$12.1M+4.8%$11.92M-8.5%
$433.18M-0.1%$434.97M+0.1%$438.62M+0.5%$439.79M+0.5%$433.47M-32.3%
$517.77M-27.4%$523.27M-28.9%$536.49M-26.8%$539.91M-25.8%$713.16M-0.5%
$129K+0.8%$129K+0.8%$128K0.0%$128K0.0%$128K+0.8%
$1.28B+3.2%$1.27B+3.4%$1.26B+3.5%$1.25B+3.4%$1.24B+3.4%
-$450.91M-28.2%-$433.81M-33.2%-$423.93M-36.5%-$396.8M-35.5%-$351.7M-28.3%
$4K+107%$4K+102%$71K+111%$29K+103%-$56K+95.8%
$828.76M-6.7%$836.56M-7.3%$838.29M-7.7%$854.04M-6.8%$888.27M-3.8%
$1.35B-15.9%$1.36B-17.0%$1.37B-16.2%$1.39B-15.2%$1.6B-2.4%
$175K$138K$179K
$175K$138K$179K
$6.61M-44.4%$7.42M-36.7%$10.53M+26.7%$9.79M+6.9%$11.89M+27.7%
$332K$174K$242K
$9.6M+59.7%$9.39M+59.6%$8.19M+46.7%$7.13M+74.9%$6.01M+34.4%
$464.83M$467.42M$464.83M
$76.7M-1.4%$78.44M-1.4%$80.15M-1.6%$82.87M-1.0%$77.8M-10.1%
$157K$36K$63K
$278.9M-15.8%$286.53M-15.6%$294.16M-15.5%$301.8M-15.3%$331.32M-9.2%
$76.7M-1.4%$78.44M-1.4%$80.15M-1.6%$82.87M-1.0%$77.8M-10.1%
$9.6M+59.7%$9.39M+59.6%$8.19M+46.7%$7.13M+74.9%$6.01M+34.4%
$76.7M-1.4%$78.44M-1.4%$80.15M-1.6%$82.87M-1.0%$77.8M-10.1%
$9.6M+59.7%$9.39M+59.6%$8.19M+46.7%$7.13M+74.9%$6.01M+34.4%
$40.58M+2.8%$47.58M-23.8%$51.3M-1.7%$48.56M-4.6%$39.49M+14.1%
$338K$386K$507K
$40.58M+2.8%$47.58M-23.8%$51.3M-1.7%$48.56M-4.6%$39.49M+14.1%
$338K$386K$507K
$342.24M+0.4%$341.86M+0.4%$341.48M+0.4%$341.1M+0.4%$340.71M-36.8%
$12.73M-31.7%$12M-4.9%$17.39M-24.4%$18.48M+7.0%$18.63M+2.7%
$338K$386K$507K
$66.29M+5.3%$67.6M-74.5%$68.83M+4.5%$70.67M+5.7%$62.94M-9.1%
$0.00$0.00$0.00
129.7M129M128.9M
$1.28B+3.2%$1.27B+3.4%$1.26B+3.5%$1.25B+3.4%$1.24B+3.4%
9.6M7.2M7.3M
$12.76$13.58$13.70
$0$0$0
$250M$250M$250M
$129.65M$128.99M$128.89M
$129.65M$128.99M$128.89M
$899K$1.24M$2.08M
$342.24M+0.4%$341.86M+0.4%$341.48M+0.4%$341.1M+0.4%$340.71M-36.8%
$0
$17.45M-16.8%$18.22M-15.3%$20.85M-8.5%$19.98M-13.2%$20.97M-10.7%
$185.94M$180.89M$170.67M
$464.83M$467.42M$464.83M
$23.67M+3.0%$21.44M+6.3%$21.99M+20.6%$22.83M+31.2%$22.98M+20.0%
$9.55M$7.16M$7.29M
$12.76$13.58$13.7

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are NeoGenomics's total assets?
NeoGenomics (NEO) holds $1.3B in total assets, down 15.9% year over year.
How much debt does NeoGenomics have?
NeoGenomics carries $66.3M in total debt against $828.8M of shareholders' equity, a debt-to-equity ratio of 0.08.
How much cash does NeoGenomics have?
NeoGenomics holds $146.1M in cash and equivalents.
Can NeoGenomics cover its short-term obligations?
Its current ratio is 4.42 — current assets exceed current liabilities.
Where does NeoGenomics's balance sheet data come from?
Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.